168 related articles for article (PubMed ID: 32156948)
1. [Two Cases of Advanced Colorectal Cancer Achieving Complete Response by FOLFOXIRI plus Bevacizumab-A Case Report].
Nemoto T; Endo S; Isohata N; Takayanagi D; Nemoto D; Aizawa M; Utano K; Togashi K; Oshibe I; Soeta N; Saito T
Gan To Kagaku Ryoho; 2019 Dec; 46(13):2410-2412. PubMed ID: 32156948
[TBL] [Abstract][Full Text] [Related]
2. [Locally Advanced Rectal Cancer Curatively Resected after Modified FOLFOXIRI plus Bevacizumab Chemotherapy-A Case Report].
Yamaguchi S; Kobayashi K; Inoue Y; Torashima Y; Ito S; Kanetaka K; Takatsuki M; Eguchi S
Gan To Kagaku Ryoho; 2020 Mar; 47(3):453-455. PubMed ID: 32381914
[TBL] [Abstract][Full Text] [Related]
3. [Two Cases of Metastatic Rectal Cancer Patients Who Received Chemotherapy with FOLFOXIRI plus Bevacizumab].
Nishii T; Uchima Y; Yamakoshi Y; Wang E; Nagashima D; Hirakawa T; Aomatsu N; Iwauchi T; Morimoto J; Nakazawa K; Tei S; Takeuchi K
Gan To Kagaku Ryoho; 2016 Nov; 43(12):1705-1707. PubMed ID: 28133105
[TBL] [Abstract][Full Text] [Related]
4. [A Case of Complete Pathological Response in a Patient with Advanced Ascending Colon Cancer That Invaded the Liver and Duodenum after FOLFOXIRI plus Bevacizumab Chemotherapy].
Naito A; Kagawa Y; Kawai K; Takeno A; Takeda Y; Ohtsuka M; Suzuki Y; Imasato M; Fujie Y; Nakaba H; Akamatsu H; Murata K
Gan To Kagaku Ryoho; 2020 Feb; 47(2):298-300. PubMed ID: 32381968
[TBL] [Abstract][Full Text] [Related]
5. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.
Cremolini C; Loupakis F; Antoniotti C; Lupi C; Sensi E; Lonardi S; Mezi S; Tomasello G; Ronzoni M; Zaniboni A; Tonini G; Carlomagno C; Allegrini G; Chiara S; D'Amico M; Granetto C; Cazzaniga M; Boni L; Fontanini G; Falcone A
Lancet Oncol; 2015 Oct; 16(13):1306-15. PubMed ID: 26338525
[TBL] [Abstract][Full Text] [Related]
6. [A Long-Survival Case of Lower Rectal Cancer with Unresectable Liver Metastases Treated with FOLFOXIRI plus Bevacizumab(BEV)].
Kagawa Y; Inoue A; Nishizawa Y; Kawai K; Ohta T; Hata T; Naito A; Komatsu H; Miyazaki Y; Tomokuni A; Motoori M; Fujitani K; Kato T; Takeda Y; Murata K
Gan To Kagaku Ryoho; 2021 Dec; 48(13):1819-1821. PubMed ID: 35046341
[TBL] [Abstract][Full Text] [Related]
7. [A Case of a Patient with Locally Recurrent Rectal Cancer Who Underwent Surgical Resection after Chemotherapy with FOLFOXIRI plus Bevacizumab].
Shigoka M; Enomoto M; Wada T; Mazaki J; Kuwabara H; Ishizaki T; Ishibashi Y; Nagakawa Y; Katsumata K; Tsuchida A
Gan To Kagaku Ryoho; 2019 Apr; 46(4):796-798. PubMed ID: 31164539
[TBL] [Abstract][Full Text] [Related]
8. [A Case of Neoadjuvant Chemotherapy with Modified FOLFOXIRI plus Bevacizumab for Transverse Colon Cancer with Invasion of the Gastric Antrum].
Kanto S; Takeji S; Okamura M; Sakikubo M; Tatsumi K; Yasuda S; Kawabe A
Gan To Kagaku Ryoho; 2020 Oct; 47(10):1517-1520. PubMed ID: 33130754
[TBL] [Abstract][Full Text] [Related]
9. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Loupakis F; Cremolini C; Masi G; Lonardi S; Zagonel V; Salvatore L; Cortesi E; Tomasello G; Ronzoni M; Spadi R; Zaniboni A; Tonini G; Buonadonna A; Amoroso D; Chiara S; Carlomagno C; Boni C; Allegrini G; Boni L; Falcone A
N Engl J Med; 2014 Oct; 371(17):1609-18. PubMed ID: 25337750
[TBL] [Abstract][Full Text] [Related]
10. [A Case of Recurrent Rectal Cancer with Acute Lower Extremity Arterial Occlusion during Treatment with Bevacizumab].
Okano M; Hara T; Hata T; Tanizaki K; Takayama O; Kim Y; Imamoto H; Hasegawa J
Gan To Kagaku Ryoho; 2023 Mar; 50(3):404-406. PubMed ID: 36927924
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial.
Masi G; Loupakis F; Salvatore L; Fornaro L; Cremolini C; Cupini S; Ciarlo A; Del Monte F; Cortesi E; Amoroso D; Granetto C; Fontanini G; Sensi E; Lupi C; Andreuccetti M; Falcone A
Lancet Oncol; 2010 Sep; 11(9):845-52. PubMed ID: 20702138
[TBL] [Abstract][Full Text] [Related]
12. Clinical and radiological response with FOLFOXIRI and bevacizumab as third-line therapy after mFOLFOX6 and FOLFIRI failure.
de Melo JV; Vieira de Melo MS; Abad MH
Anticancer Drugs; 2011 Jun; 22 Suppl 2():S19-20. PubMed ID: 21768793
[TBL] [Abstract][Full Text] [Related]
13. FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials.
Cremolini C; Loupakis F; Masi G; Lonardi S; Granetto C; Mancini ML; Chiara S; Moretto R; Rossini D; Vitello S; Allegrini G; Tonini G; Bergamo F; Tomasello G; Ronzoni M; Buonadonna A; Bustreo S; Barbara C; Boni L; Falcone A
Ann Oncol; 2016 May; 27(5):843-9. PubMed ID: 26861604
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
Cremolini C; Casagrande M; Loupakis F; Aprile G; Bergamo F; Masi G; Moretto R R; Pietrantonio F; Marmorino F; Zucchelli G; Tomasello G; Tonini G; Allegrini G; Granetto C; Ferrari L; Urbani L; Cillo U; Pilati P; Sensi E; Pellegrinelli A; Milione M; Fontanini G; Falcone A
Eur J Cancer; 2017 Mar; 73():74-84. PubMed ID: 27986363
[TBL] [Abstract][Full Text] [Related]
15. [A Patient with Recurrent Ulcerative Colitis-Associated Rectal Cancer Attaining a Complete Response with FOLFIRI plus Bevacizumab].
Iseki Y; Maeda K; Shibutani M; Nagahara H; Ikeya T; Tamura T; Ohira G; Sakurai K; Yamazoe S; Kimura K; Toyokawa T; Kubo N; Tanaka H; Muguruma K; Hirakawa K
Gan To Kagaku Ryoho; 2015 Nov; 42(12):2205-7. PubMed ID: 26805312
[TBL] [Abstract][Full Text] [Related]
16. [A Case of a Patient with Rectum Cancer with Multiple Metastases, Who Was Able to Undergo Conversion Therapy Using Alternating mFOLFOX6 and FOLFIRI Regimens in Combination with Alternating Cetuximab and Bevacizumab].
O'hara H; Yamamoto H
Gan To Kagaku Ryoho; 2018 Nov; 45(11):1669-1672. PubMed ID: 30449861
[TBL] [Abstract][Full Text] [Related]
17. Outcome of second-line treatment after first-line chemotherapy with the GONO FOLFOXIRI regimen.
Fornaro L; Vasile E; Masi G; Loupakis F; Baldi GG; Allegrini G; Salvatore L; Cremolini C; Cupini S; Cortesi E; Tuzi A; Granetto C; Brunetti IM; Ricci S; Falcone A
Clin Colorectal Cancer; 2012 Mar; 11(1):71-6. PubMed ID: 21903485
[TBL] [Abstract][Full Text] [Related]
18. [A Case of Bilateral Lymph Node Metastases of Rectal Cancer Treated with Chemotherapy and Surgery].
Tate T; Fukui Y; Tomizawa K; Hanaoka Y; Toda S; Matoba S; Kuroyanagi H
Gan To Kagaku Ryoho; 2017 Oct; 44(10):871-873. PubMed ID: 29066682
[TBL] [Abstract][Full Text] [Related]
19. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest.
Falcone A; Ricci S; Brunetti I; Pfanner E; Allegrini G; Barbara C; Crinò L; Benedetti G; Evangelista W; Fanchini L; Cortesi E; Picone V; Vitello S; Chiara S; Granetto C; Porcile G; Fioretto L; Orlandini C; Andreuccetti M; Masi G;
J Clin Oncol; 2007 May; 25(13):1670-6. PubMed ID: 17470860
[TBL] [Abstract][Full Text] [Related]
20. [A Case of Descending Colon Adenocarcinoma with Neuroendocrine Differentiation Successfully Treated with FOLFIRI plus Bevacizumab].
Kakuta S; Takayama W; Kou T; Satou M; Sugaya M
Gan To Kagaku Ryoho; 2016 Jan; 43(1):129-32. PubMed ID: 26809541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
